To our knowledge, efficacy against indices of neuropathic pain in diabetes has not been studied but may be predicted by the involvement of decreased spinal KCC2 and disrupted GABAergic inhibitory systems. The gene discussed is SLC12A5; the disease is diabetes mellitus.